Stryker Co. (NYSE:SYK) Shares Sold by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. trimmed its holdings in Stryker Co. (NYSE:SYK) by 4.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 18,099 shares of the medical technology company’s stock after selling 889 shares during the period. Crossmark Global Holdings Inc.’s holdings in Stryker were worth $6,517,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Dunhill Financial LLC boosted its position in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Centennial Bank AR grew its stake in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares during the period. Darwin Wealth Management LLC acquired a new stake in shares of Stryker during the 3rd quarter worth $36,000. HBW Advisory Services LLC purchased a new position in shares of Stryker in the 3rd quarter worth $42,000. Finally, Hara Capital LLC acquired a new position in Stryker in the third quarter valued at $42,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insider Activity

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on SYK. Citigroup raised their price objective on Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Wells Fargo & Company raised their price target on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. StockNews.com downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Tuesday, January 7th. Finally, BTIG Research upped their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $405.80.

Stryker Price Performance

SYK opened at $395.86 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. Stryker Co. has a 1-year low of $307.23 and a 1-year high of $398.20. The company has a 50-day moving average of $375.61 and a 200-day moving average of $359.53. The company has a market capitalization of $150.91 billion, a P/E ratio of 42.43, a PEG ratio of 2.63 and a beta of 0.95.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. During the same quarter in the previous year, the firm earned $2.46 earnings per share. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. Equities analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio (DPR) is 36.01%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.